-
公开(公告)号：US11919910B2
公开(公告)日：2024-03-05
申请号：US17983474
申请日：2022-11-09
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Xuechao Xing , Yong He , Matthew C. Rhodes , Yat Sun Or
IPC: C07D487/10 , A61P31/14
CPC classification number: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11912714B2
公开(公告)日：2024-02-27
申请号：US17983501
申请日：2022-11-09
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Hui Cao , Wei Li , Xuri Gao , Jiajun Zhang , Xiaowen Peng , Jorden Kass , Ruichao Shen , Guoqiang Wang , Yat Sun Or
IPC: C07D487/10 , A61P31/14
CPC classification number: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
3.发明授权
公开(公告)号：US11834436B2
公开(公告)日：2023-12-05
申请号：US17228815
申请日：2021-04-13
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D413/14 , C07D405/14 , C07D409/14 , C07D417/14
CPC classification number: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
-
公开(公告)号：US20230295175A1
公开(公告)日：2023-09-21
申请号：US18122892
申请日：2023-03-17
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Kaicheng Zhu , Tao Wang , Xin Zhang , Xiaowen Peng , Ruichao Shen , Jiajun Zhang , Wei Li , Hui Cao , Xuri Gao , Guoqiang Wang , George G. Wu , Yat Sun Or
IPC: C07D487/10
CPC classification number: C07D487/10
Abstract: The present invention relates to processes for preparing a compound of Formula (A):
or a pharmaceutically acceptable salt or solvate thereof. Compound of Formula (A) and pharmaceutical compositions are useful as SARS-CoV-2 3CL pro inhibitors.
-
公开(公告)号：US20230143250A1
公开(公告)日：2023-05-11
申请号：US17891436
申请日：2022-08-19
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Jun Ma , Brett Granger , Jiang Long , Bin Wang , Sourav Ghorai , Jing He , Yong He , Xuechao Xing , Ruichao Shen , Yat Sun Or
IPC: C07D265/36 , C07D277/36 , C07C311/29 , C07D217/20 , C07D471/04 , C07D209/18 , C07D209/44 , C07D417/12 , C07D417/04 , C07D307/81
CPC classification number: C07D265/36 , C07D277/36 , C07C311/29 , C07D217/20 , C07D471/04 , C07D209/18 , C07D209/44 , C07D417/12 , C07D417/04 , C07D307/81
Abstract: The present invention provides compounds of Formula (I),
pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.
-
公开(公告)号：US20230122228A1
公开(公告)日：2023-04-20
申请号：US17720603
申请日：2022-04-14
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Ruichao Shen , Yong He , Xuechao Xing , Matthew C. Rhodes , Joseph D. Panarese , Samuel Bartlett , Wei Li , Hui Cao , Jiajun Zhang , Xiaowen Peng , Guoqiang Wang , Yat Sun Or
IPC: C07D487/10 , A61P31/14 , A61P11/00 , A61K9/00
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20220356167A1
公开(公告)日：2022-11-10
申请号：US17197399
申请日：2021-03-10
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US11345699B2
公开(公告)日：2022-05-31
申请号：US16688429
申请日：2019-11-19
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jing He , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Bin Wang , Yat Sun Or
IPC: C07D471/04 , C07D401/14 , C07D417/14 , C07D405/14 , C07D413/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US11339170B1
公开(公告)日：2022-05-24
申请号：US17479455
申请日：2021-09-20
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Xuri Gao , Wei Li , Jiajun Zhang , Xiaowen Peng , Hui Cao , Jorden Kass , Ruichao Shen , Guoqiang Wang , Yat Sun Or
IPC: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
10.发明申请
公开(公告)号：US20220119366A1
公开(公告)日：2022-04-21
申请号：US17228815
申请日：2021-04-13
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D413/14 , C07D405/14 , C07D409/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
